Evobrutinib, a covalent Bruton’s tyrosine kinase inhibitor: Mass balance, elimination route, and metabolism in healthy participants

Autor: Holger Scheible, Martin Dyroff, Annick Seithel‐Keuth, Eleanor Harrison‐Moench, Nadra Mammasse, Andreas Port, Angelika Bachmann, Jennifer Dong, Jan Jaap vanLier, William Tracewell, David Mitchell

Publikováno v: Clinical and Translational Science, Vol 14, Iss 6, Pp 2420-2430 (2021)

Abstract The highly selective, covalent Bruton’s tyrosine kinase inhibitor evobrutinib is under investigation for treatment of patients with multiple sclerosis (MS). Early clinical studies in healthy participants and patients with relapsing MS indi

Externí odkaz: https://doaj.org/article/489421b638da46dbad0cbcea83c71c6e

Evobrutinib, a covalent Bruton’s tyrosine kinase inhibitor: Mass balance, elimination route, and metabolism in healthy participants

Autor: Eleanor Harrison-Moench, Jan J. van Lier, Jennifer Dong, Angelika Bachmann, David Mitchell, Andreas Port, Nadra Mammasse, Annick Seithel-Keuth, Martin Dyroff, William Tracewell, Holger Scheible

Publikováno v: Clinical and Translational Science, Vol 14, Iss 6, Pp 2420-2430 (2021)
Clinical and Translational Science

The highly selective, covalent Bruton’s tyrosine kinase inhibitor evobrutinib is under investigation for treatment of patients with multiple sclerosis (MS). Early clinical studies in healthy participants and patients with relapsing MS indicated tha

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::918d725112442079a32e919b8e766712
https://doi.org/10.1111/cts.13108

Pharmacokinetics and Pharmacodynamics of a Proposed Pegfilgrastim Biosimilar MSB11455 Versus the Reference Pegfilgrastim Neulasta in Healthy Subjects: A Randomized, Double-blind Trial

Autor: Martin Ullmann, Michael Stahl, Corinne Seng Yue, Vishal Ghori, Paul M. Griffin, Jason D. Lickliter, Radmila Kanceva, Eleanor Harrison-Moench, Emmanuelle Vincent, Armin Schueler

Publikováno v: Clinical therapeutics. 42(8)

Purpose MSB11455 is a proposed biosimilar to the reference pegfilgrastim (Neulasta®). This pivotal equivalence study (NCT03251248) assessed the pharmacokinetic and pharmacodynamic equivalence of MSB11455 to the reference product. Methods This 2-way,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::becec179a260790cc00d37346a09e1e4
https://pubmed.ncbi.nlm.nih.gov/32660769

Selection of the recommended phase 2 dose (RP2D) for M7824 (MSB0011359C), a bifunctional fusion protein targeting TGF-β and PD-L1

Autor: Akash Khandelwal, Isabelle Dussault, James L. Gulley, Justin J. Wilkins, Andre Koenig, Yulia Vugmeyster, Wanping Geng, Eleanor Harrison-Moench, Liang Cao

Publikováno v: Journal of Clinical Oncology. 36:2566-2566

2566Background: The transforming growth factor β (TGF-β) pathway plays an important role in tumor immune escape and may enhance the response to PD-L1 monoclonal antibodies (mAb). M7824 is an innova...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a2dcfef2c6695ac6c3a0320c50a0168a
https://doi.org/10.1200/jco.2018.36.15_suppl.2566

Bioactivation and reactivity research advances – 2021 year in review.

Autor: Jackson, Klarissa D.¹ (AUTHOR), Argikar, Upendra A.² (AUTHOR), Cho, Sungjoon³ (AUTHOR), Crouch, Rachel D.⁴ (AUTHOR), Driscoll, James P.⁵ (AUTHOR), Heck, Carley J. S.⁶ (AUTHOR), King, Lloyd⁷ (AUTHOR), Maw, Hlaing⁸ (AUTHOR), Miller, Grover P.⁹ (AUTHOR), Seneviratne, Herana Kamal¹⁰ (AUTHOR), Wang, Shuai³ (AUTHOR), Wei, Cong¹¹ (AUTHOR), Zhang, Donglu³ (AUTHOR), Khojasteh, S. Cyrus³ (AUTHOR) klarissa.jackson@unc.edu, Garrido, Claudia (AUTHOR), Leimkuhler, Silke (AUTHOR), Sun, Chen (AUTHOR), Zhao, Huimin (AUTHOR), Li, Wei (AUTHOR), Jia, Yudi (AUTHOR)

Publikováno v: Drug Metabolism Reviews. Aug2022, Vol. 54 Issue 3, p246-281. 36p.